Oxford-based , a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed as CEO.聽
As Founder of 17c起草视频, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease 鈥� developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug candidates towards the clinic.
With two major pharma partnership deals with GSK and Boehringer Ingelheim underway, 17c起草视频 is identifying disease modifying targets and RNA therapies that have the potential to reverse fibrosis, cirrhosis and other end-stage liver diseases. 17c起草视频 is driving progress in a space that has long lacked options for patients by use of its world leading liver perturbation atlases.
Eliot Forster, Ph.D, Chair of the Board of Directors at 17c起草视频 said: 鈥淚鈥檓 delighted to announce Quin鈥檚 appointment as CEO of 17c起草视频. Quin鈥檚 appointment is excellent news for 17c起草视频, its investors and the treatment of liver diseases. I鈥檓 personally delighted to continue to work with Quin and look forward to even greater progress under his leadership.鈥�
Quin has dedicated his life鈥檚 work to finding breakthrough treatments for late stage liver disease. With his medical training, and degrees in genetics and mathematics from Oxford and Cambridge Universities, Quin founded his first drug discovery company in liver genomics 20 years ago. He鈥檚 since made significant steps in researching the genetic drivers of chronic liver disease and pioneering novel treatments.
Now, at 17c起草视频, Quin oversees the world鈥檚 largest perfused liver lab in New York, where the company is using human models to make AI-incorporated drug discovery a clinical reality.
, Founder and CEO at 17c起草视频, said: 鈥�We started 17c起草视频 almost six years ago with a simple mission: to rewrite the future for people living with chronic liver disease. I could not be more thrilled to now be steering our therapies towards the clinic. Getting medicines to patients has been a deeply personal journey of twenty years in liver research.鈥�